Business Scope

Cellular Therapy

Introduction

Currently, the Group has established five cell storage, preparation and therapy centers in Tianjin, Suzhou (Jiangsu Province), Changzhou (Jiangsu Province) and Hong Kong to make a good planning layout serving the cell business globally.

Products

Tianjin Weikai
The Group’s subsidiary 天津衛凱生物工程有限公司 (Tianjin Weikai Bioeng Ltd#) focuses on theR&D and applications of cell culture equipment and cell products, as well as providing cell-related outsourcing technical services. The self-developed 3DFlo cell culture instrument ensured the high quality cell reproduction and established an in vitro model to simulate in-vivo physical condition by utilizing automated continuous perfusion cell culture technology. Meanwhile, Tianjin Weikai has established a close cooperation relationship with Institute of Chemical Physics, Chinese Academy of Sciences and other scientific research institutes at home and abroad.

AK Suzhou
In 2016, the Group’s subsidiary 奧凱(蘇州)生物技術有限公司 (AK (Suzhou) Biomedical Ltd#) expanded the Phase II Cell Preparation Center. It provides high standards of service and equipment for cell clinical research, testing and applications leveraging on the Oxford R&D team’s unique cell processing technology and reagent formula. Its core technologies include human cell separation, purification, cultivation, amplification, storage and transportation, as well as the development and production of automated closed cell bioreactors.

Changzhou branch company, Jiangsu Province
In October 2016, the Group started to build a Cell Storage and Preparation Center in Changzhou, Jiangsu Province. The center has been identified as the technology transformation unit of Engineering Technology Research Center for Tumor Immunotherapy of Jiangsu Province, mainly responsible for industrial transformation and clinical applications of the R&D results achieved by the center. The scope of business mainly covers cellular therapy, cell storage, genetic testing, biological agents manufacturing. The center is scheduled to be completed by the end of 2017.

Hong Kong International Regenerative Centre
The Hong Kong International Regenerative Centre (“HKIRC”), being the first large-scale comprehensive health care base for precision medicine in Hong Kong, was established by the Group at the Miramar Center in Tsim Sha Tsui, Hong Kong. In possession of precise medical technology, combining with precise physical examination and genetic testing, HKIRC aims to provide precise healthcare to meet the physical and mental needs from customers, including precise cellular therapy and precise medical beauty.

BioCell Technology Limited (“BioCell”)
Our China Stem Cell Clinical Applications Centre (the“Centre”), located at Phase 3 of Hong Kong Science Park in Shatin, has started construction. Covering an area of 2,000 square meters, the Center is designed in accordance with international standards and is equipped with advanced equipment and facilities in high specifications. Stem cell clinical application facilities meet the clean room standards from EMA, FDA, CFDA, TGA and GMP PIC/S. As Asia’s first international cell and gene preparation center, the Centre provides cell preparation processes for international biotechnology companies, international pharmaceutical plants, clinical application institutions and cell libraries in line with international and domestic cell preparation quality standards, as well as technology platforms for clinical application transformation for the improvement and development of the cellular therapy in the future. We will conduct pre-installation regulatory reviews in accordance with the GMP and PIC/S specifications from the Hong Kong Department of Health. The Centre has established close cooperative relationship with relevant research departments and academics, including The University of Hong Kong and The University of Oxford, laying a solid foundation for the clinical transformation and industrialization of stem cell and cellular therapy technology and for cell preparation platforms in Hong Kong and other Asian regions. Since the construction work and installation and commissioning of equipment have been completed, the Centre has been officially put into operation in June 2017.

Company Introduction

BIOCELL TECHNOLOGY LIMITED
Located in Hong Kong Science Park, the cell production centre covers more than 2,000m2. This centre is designed to comply with EMA, FDA, TGA, CFDA GMP as well as international GMP PIC/S requirements which are observed in Hong Kong. Equipped with the most advanced cell manufacturing technologies, equipment whilst observing strict standard operating procedures, it aims to become the first international cell and gene production centre in Asia, which provides international bio-tech enterprises, pharmaceutical companies, clinical application institutes and cell banks with bioprocessing capacities complying with both domestic and international quality standards and a translational platform for clinical applications.

Besides, the centre has built up close partnership with research institutes and scholars, including The University of Hong Kong Li Ka Shing Faculty of Medicine and University of Oxford, to facilitate the industrialization of stem cell and cell therapy. The cell production platform also lays a solid foundation for the cell and gene therapy development in Hong Kong and Asia.

Address: Hong Kong science park 15 w7 floor

HONG KONG INTERNATIONAL REGENERATIVE CENTER
The Hong Kong International Regenerative Center (HKIRC) is a wholly-owned subsidiary of CRMI. It is the first comprehensive facility for precision medicine in Hong Kong.[For anti aging] With precise medical technology combined with accurate physical examination and genetic testing, HKIRC provides various personalized medical treatments for physical and mental health needs, including personalized cell therapy and hormone replacement therapy, customised cosmetic and aesthetic medicine, as well as plastic surgery and psychological counseling. HKIRC helps you[Original = customer. you?] maintain young and healthy physically and mentally.

Address: 23/F, Miramar Tower, 132 Nathan Rd., T.S.T., Kowloon

TIANJIN WEIKAIBIOENG LTD.
Tianjin Wei Kai Biological Engineering Co., Ltd (“Wei Kai Bioeng”) is a national hi-tech enterprise which specializes in developing cell culture devices, research and application of cell-based products as well as outsourcing cell-based services. The 3DFlo Cell culture system is one of the most outstanding achievements of Wei Kai Bioeng's independent research and development team. Traditional petri dish, culture flask and microplate require a lot of time and skilled manpower to use and can even result in cross contamination when culturing cells. This system capitalizes on the automatic and continuous perfusion culture technique, which significantly reduces the time and manpower needed and eliminates cross contamination risk, and guarantees the quality of cells produced. With these done, an in vitro model was built to mimic in vivo physiological conditions. Products and techniques developed by Wei Kai Bioeng can be applied to 3D culture of almost all cell types, which include cell lines, primary cells, cells and co-culture of multiple cells. The application scope of this system includes cancer research and drug analysis, cell biology research and tissue engineering, absorption, distribution, metabolism, excretion and ADME-TOX test and DMPK.

Address: Starfish Plaza, Tianjin Binhai Tanggu Marine Hi-Tech Development Area
Website:www.weikaibioeng.com

AK (SUZHOU) BIOMEDICAL LTD.
AK Biomedical Ltd., located in Suzhou Industrial Park, owns a GMP-compliant cell processing platform. The company is also officially recognized by the Jiangsu Province government as an Innovation & Entrepreneurship Team business as well as an Overseas Academician Workstation.

The company’s Oxford based R & D team provides unique and advanced cell processing techniques and reagent formulations for AK, as well as experience and in depth know-how in the relevant field. This allows AK to provide customers and partners with services and equipment of the highest standard for the clinical applications associated with cells. The company specializes in the separation, isolation, expansion, cryo-storage and transportation of human cells, as well as the development and production of automated closed system cell expansion equipments. The company complies with the highest standard GMP and quality control system in order to satisfy the strict requirements of Chinese Food and Drug Administration (CFDA), as well as the regulations and requirements of the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). In collaboration with the Group, AK also actively participates in formulating of national and industry standards and rules.

Address: Suite 301, Building B5, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, China
Website:www.akbiomedical.com

JIANGSU YIZE BIOTECHNOLOGY CO., LTD
Jiangsu Yize Biotechnology Co., Ltd. is a technology translation unit under Jiangsu Engineering Technology Research Center for Tumor Immunotherapy. The company is mainly responsible for the industrialisation and clinical application of the center’s R&D achievements. The business scope of the company includes cell therapy, cell storage, genetic testing, biological reagent manufacture and big medical data, allowing the company to become a leading biotechnology enterprise integrated with production, treatment and R&D.

Address: A3-701 Zhongke Entrepreneurship Center, Changzhou Science and Education City, Changwu Middle Road No.18, Wujin District, Changzhou City

IR Contact

China Regenerative Medicine International Limited

A:

10/F, Dah Sing Financial Center, 108 Gloucester Road, Wan chai, Hong Kong

E: info@crmi.hk|

T: +852 3966 8388 |

F: +852 2802 0026